**Major Events**

Shuangdeng Group (06960) to conduct IPO from August 18-21, planning to globally offer 58.557 million H-shares with Sanshui Venture Capital introduced as cornerstone investor

SUNAC (01918) plans to issue mandatory convertible bonds and adopt team stabilization plan

Yasheng Biopharma-B (06855): Lishengto® global registration Phase III clinical study for first-line treatment of intermediate-to-high-risk MDS patients approved by U.S. FDA and European EMA

361 Degrees (01361) subsidiary enters strategic cooperation agreement with Standard

Eagle Nice Precision (01286): Additional tariffs may impact business and operations

Luye Pharma (02186): Ruoxinlin® China Phase III clinical trial for generalized anxiety disorder completes patient enrollment

Tiantu Capital (01973) signs strategic cooperation memorandum with HashKey Capital, planning to establish virtual asset investment fund

China Rare Earth (03788): Mt Bundy and Cygnet gold projects expected to achieve annual gold production exceeding 200,000 ounces

**Operating Performance**

New China Life Insurance (01336) reports cumulative original insurance premium income of 137.806 billion yuan in first 7 months, up 23% year-on-year

SINO BIOPHARM (01177) releases interim results with revenue of 17.57 billion yuan, up 10.7% year-on-year

MEITU (01357) releases interim results with shareholders' attributable profit of 397 million yuan, up 30.84% year-on-year; both MAU and paid subscription users achieve strong growth

Xtep International (01368) releases 2025 interim results with shareholders' attributable profit of 914 million yuan, up 21.47% year-on-year

LEAPMOTOR (09863) achieves first positive semi-annual net profit with H1 net profit of 33.03 million yuan

Hansoh Pharma (03692) releases interim results with shareholders' attributable profit of 3.135 billion yuan, up 15.02% year-on-year

Lee's Pharm (00867) announces interim results with owners' attributable profit of approximately 941 million yuan, up 3.38% year-on-year

CStone Pharmaceuticals-B (06990) releases interim results with revenue of 950 million yuan and R&D expenses of 612 million yuan

Sinopec Oilfield Service (01033) announces H1 results with net profit attributable to parent company of approximately 492 million yuan, up 9% year-on-year

Onewo (02602) releases interim results with shareholders' attributable profit of 792 million yuan, up 3.88% year-on-year

Yunfeng Financial (00376) issues profit alert, expecting H1 net profit attributable to equity shareholders of approximately 480 million HK dollars, up approximately 139% year-on-year

United Laboratories (03933) issues profit alert, expecting interim net profit of approximately 1.85 billion yuan, up year-on-year

MEDBANKS Network Technology (00314) releases interim results with overall gross margin significantly improving 4.7 percentage points year-on-year to 14.4%

Orange Sky Golden Harvest (01132) issues profit alert, expecting H1 net profit attributable to shareholders of no less than 125 million HK dollars, turning from loss to profit year-on-year

SJM Holdings (00327) releases interim results with shareholders' attributable profit of 391 million HK dollars, proposing interim dividend of 0.25 HK dollars per share

WuXi AppTec (02268) releases interim results with shareholders' attributable net profit of 746 million yuan, up 52.74% year-on-year

Dalian Wanda Commercial Properties (00207) reports H1 contract sales of approximately 2.749 billion yuan, down 81.4% year-on-year